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Abstract
Purpose Postoperative assessment of acromegaly activity is typically performed at least 3 months after neurosurgery (NS). 
Few studies have evaluated the use of early postoperative growth hormone (GH) levels as a test to predict short- and long-term 
remission of acromegaly. Our objective was to evaluate the diagnostic performance of serum random GH on a postoperative 
day one (D1-rGH) and two (D2-rGH), particularly in predicting long-term disease persistence.
Materials and methods Forty-one subjects with acromegaly who were undergoing NS were enrolled (mean age ± SD 
47.4 ± 13.1 years at diagnosis; women 54%; macroadenomas 71%). The final assessment of disease activity was performed 
one year after NS. ROC curves were used to evaluate the diagnostic performance of D1-rGH and D2-rGH.
Results After a 1-year follow-up, the overall remission rate was 55%. ROC analysis identified an optimal D1-rGH cut-off 
value of 2.1 ng/mL for diagnosing long-term disease persistence (55.6% SE; 90.9% SP). The cut-off point became 2.5 ng/mL 
after maximizing specificity for disease persistence (yielding a 100% positive predictive value) and 0.3 ng/mL after maxi-
mizing sensitivity for disease remission. The optimal D2-rGH cut-off value was 0.6 ng/mL (81.8% SE; 50% SP); the cut-off 
point became 2.9 ng/mL after maximizing specificity and 0.1 ng/mL after maximizing sensitivity, with no clinical utility.
Conclusions D1-rGH could be a highly specific test for the early diagnosis of long-term acromegaly persistence, which 
is predicted by a value > 2.5 ng/mL with a great degree of certainty. The diagnostic performance of D2-rGH was insuf-
ficient. Further research is required to validate these preliminary results prior to modifying the postoperative management 
of acromegaly.
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Introduction
Neurosurgery (NS) is considered the first choice to cure 
acromegaly. In the literature, the remission rate is variable 
(56 − 72%) depending on the clinical center and operator [1]. 
Moreover, the probability of remission is different between 
micro- (> 85%) and macroadenomas (40 − 50%) [2]. Tech-
nical progress has improved surgical outcomes to achieve 
a post-NS remission rate of 60 − 85% in the largest cohorts 
[3, 4].
Re-evaluation of the disease state after NS is typically 
performed by measuring IGF1 and nadir GH after an oral 
glucose tolerance test (OGTT) at least 12 weeks post-inter-
vention due to the long half-life of IGF1 [2, 5].
The American Association of Clinical Endocrinologists 
(AACE) guidelines for acromegaly recommend that “a fast-
ing GH level be measured early postoperatively” to predict 
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long-term remission (recommendation n. 47, “best evidence” 
level 2, Grade C) [6]. In fact, the short half-life of GH could 
allow the early prediction of the disease state. Soon after NS, 
GH levels decrease as a result of the ischemia and fibrosis of 
residual adenomatous tissue or adenoma removal; the only 
source of GH production should be normal somatotropic 
cells, which are still suppressed by the previously high levels 
of GH and IGF1 [7].
Postoperative cortisol is a recognized predictor of Cush-
ing disease remission, while in acromegaly, the use of post-
operative GH has not yet been fully explored.
Some studies have attempted to assess the prognostic role 
of early random GH determination with different cut-off 
levels and times, as well as other early postoperative bio-
chemical tests (mean GH, IGF1, nadir GH after OGTT); 
however, many pitfalls must be considered to avoid incorrect 
decisions. In fact, in comparison with GH, the decline in 
IGF1 is delayed due to the longer half-life of IGF-binding 
proteins. Nadir GH after an OGTT may slightly change over 
time, from immediately postoperatively to 3 months after 
NS [8]. A prospective study evaluated the predictive role of 
random GH and IGF1 on a postoperative day one and nadir 
GH following an OGTT 2 − 4 days after NS [9]. The authors 
showed that early determination of IGF1 was not useful for 
predicting disease state; however, the proposed cut-offs for 
random GH and nadir GH appeared to demonstrate good 
positive predictive values for remission but inadequate speci-
ficity [9].
Early random GH could be considered a simple and cheap 
test that is entirely feasible for the postoperative manage-
ment of acromegaly; a specific and reproducible cut-off point 
is needed to discriminate between cured patients and those 
with a high risk of persistent or recurrent disease.
The present study aimed to evaluate the diagnostic per-
formance of GH determination on postoperative days one 
and two for the early prediction of acromegaly persistence 
at 1 year after pituitary surgery.
Materials and methods
We prospectively recruited 41 consecutive subjects with 
acromegaly who were undergoing NS for pituitary adenoma 
at the Division of Neurosurgery of the “City of Health and 
Science of Turin” University Hospital (Turin, Italy) between 
2014 and 2018. All surgical procedures were performed by 
a single neurosurgeon dedicated to pituitary surgery (FZ), 
using a 3D endoscopic endonasal approach; only one patient 
needed a combined transcranial and endonasal approach due 
to a “supergiant” GH-secreting pituitary adenoma [10].
Serum IGF1 was assessed at diagnosis and three months 
and one year after NS. Serum random GH (rGH) was 
assessed on day one, day two, and three months after NS. 
Nadir GH after an OGTT (nGH) was measured three months 
after NS; adequate inhibition of GH after the OGTT was 
defined as nGH < 1.0 ng/ml.
Contrast-enhanced magnetic resonance imaging was per-
formed three months after NS.
Acromegaly persistence at the end of the one-year follow-
up was defined as the use of medical therapy or the need 
for radiation therapy due to disease persistence or recur-
rence after NS, or an IGF1 value above the age-dependent 
upper limit of normal (ULN) of the Italian population [11], 
expressed as both absolute value and IGF1 times ULN 
(IGF1 × ULN); on the contrary, disease remission was 
defined by an IGF1 value below the age-dependent ULN 
of the Italian population, without active medical therapy or 
exposure to radiation therapy.
Serum GH levels (ng/mL) were measured using an immu-
noradiometric assay (IRMA GH, Beckman Coulter, Czech 
Republic), and serum IGF1 levels (ng/mL) were measured 
by a radioimmunoassay technique (SM-C-RIA-CT, DIA-
source ImmunoAssays, Belgium) following acid–ethanol 
extraction to avoid interference of binding proteins.
Data are presented as the mean ± standard deviation (SD), 
or the median (interquartile range) for skewed variables. 
Statistical analysis was performed using the Stata program 
(version 14; Stata Corporation, College Station, TX, USA). 
The Mann − Whitney U test was employed for continuous 
variables, whose non-normal distribution was attributed to 
the limited sample size, and the chi-square test was used for 
categorical variables.
Receiver Operating Characteristics (ROC) analysis was 
carried out to identify the D1- and D2-rGH cut-off values 
with the optimal sensitivity/specificity pairing, the highest 
specificity for acromegaly persistence, and the highest sen-
sitivity for disease remission.
Results
The demographic and clinical characteristics of the partici-
pants are summarized in Table 1. Of the 41 subjects, 54% 
were women. The mean age was 47.4 ± 13.1 years at diag-
nosis and 49.0 ± 12.5 years at NS. All patients were affected 
by a GH-secreting pituitary adenoma (71% macroadenomas) 
with a median diameter of 12 mm (8 − 21).
At diagnosis, the median IGF1 was 848  ng/mL 
(546 − 1105) and the median IGF1 (x ULN) was 2.9 
(1.9 − 3.7). Neoadjuvant therapy with a somatostatin analog 
was given to 42% of patients and discontinued at least 
3 months prior to NS to avoid pharmacological interference 
in subsequent biochemical assessments.
Three months after NS, a residual adenoma was found in 
34% of patients by contrast-enhanced magnetic resonance 
imaging. Among these, 71% had originally been affected by 
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macroadenomas, but in comparison with microadenomas, 
the higher percentage was not statistically significant.
On postoperative day one (D1), the median rGH 
(D1-rGH) was 1.4 ng/mL (0.9 − 2.4; n = 41) and on post-
operative day two (D2), the median rGH (D2-rGH) was 
0.9 ng/mL (0.3 − 1.7; n = 30). After 3 months, the median 
IGF1 was 249 ng/mL (194.5 − 424; n = 40) and the median 
IGF1 (x ULN) was 0.9 (0.7 − 1.5); 65% of the values were 
within the reference range. The median rGH was 1.0 ng/
mL (0.4 − 3.8; n = 38) and the median nGH was 0.3 ng/mL 
(0.1 − 0.8; n = 36); 77.8% of subjects achieved an adequate 
inhibition of GH after the OGTT. After 1 year, the median 
IGF1 was 226 ng/mL (162 − 364; n = 41), and the median 
IGF1 (x ULN) was 0.7 (0.6 − 1.2). The overall remission 
rate was 55%, with no difference between macro- and 
microadenomas (57% vs. 50%; NS).
Using the ROC curves to predict long-term disease per-
sistence, both sensitivity (SE) and specificity (SP) were 
optimized for D1-rGH at a cut-off value of 2.1 ng/mL, 
yielding 55.6% SE, 90.9% SP, a positive likelihood ratio 
(LH) of 6.11, a negative LH of 0.49, and an area under the 
curve (AUC) of 0.783 ± 0.075. Three months after NS, 
among the subjects with a D1-rGH ≤ 2.1 ng/mL, 82.7% 
showed IGF1 normalization, as well as GH inhibition after 
the OGTT. Among those with a D1-rGH > 2.1 ng/mL, 
16.6% achieved IGF1 normalization and 33.3% reached 
GH inhibition after the OGTT. The one-year remission rate 
was 69% among subjects with a D1-rGH ≤ 2.1 ng/mL and 
16.6% among those with a D1-rGH > 2.1 ng/mL.
After maximizing specificity for acromegaly persis-
tence, the ROC analysis identified a cut-off value of 2.5 ng/
mL (100% SP; 44.4% SE). A D1-rGH > 2.5 ng/mL was 
observed in eight of the 41 subjects (19.5%), among which 
75% were women, 62% had originally been affected by 
macroadenomas, and 25% did not have a visible residual 
tumor. Three months after NS, 78.8% of the subjects with a 
D1-rGH ≤ 2.5 ng/mL showed IGF1 normalization and 84.8% 
showed GH inhibition after the OGTT. On the contrary, no 
patients with a D1-rGH > 2.5 ng/mL achieved IGF1 normali-
zation or GH inhibition after the OGTT. One year after NS, 
67% of subjects with a D1-rGH ≤ 2.5 ng/mL achieved remis-
sion as compared with 0% of those with a D1-rGH > 2.5 ng/
mL. The proposed cut-off for the detection of acromegaly 
persistence after 1 year yielded a 44.4% SE, a 100% SP, a 
100% positive predictive value, a 69% negative predictive 
value, and a 75% accuracy.
After maximizing the sensitivity for disease remission, 
the ROC curves provided a cut-off value of 0.3 ng/mL 
(100% SE; 0% SP). In our population, only three of the 41 
subjects (7%) had a D1-rGH of 0.3 ng/mL, and none had a 
D1-rGH < 0.3 ng/mL; thus, further statistical analysis was 
Table 1  Demographic and clinical features of the study population
Data are presented as the mean ± SD or the median (interquartile 
range)
Characteristics All subjects (n = 41)
Gender
 Women, n (%) 22 (54)
 Men, n (%) 19 (46)
Age, years 47.4 ± 13.1
Neoadjuvant therapy, n (%) 17 (42)
 Adenoma diameter, mm 12 (8 − 21)
 Microadenoma, n (%) 12 (29)
 Macroadenoma, n (%) 29 (71)
Residual, n (%) 14 (34)
 Microadenoma, n (%) 4 (29)
 Macroadenoma, n (%) 10 (71)
IGF1, ng/mL; IGF1 (x ULN)
 At diagnosis 848 (546 − 1105); 2.9 (1.9 − 3.7)
 Three months after NS 249 (194.5 − 424); 0.9 (0.7 − 1.5)
 One year after NS 226 (162 − 364); 0.7 (0.6 − 1.2)
Random GH, ng/mL
 Postoperative day one 1.4 (0.9 − 2.4)
 Postoperative day two 0.9 (0.3 − 1.7)
 Three months after NS 1.0 (0.4 − 3.8)
Nadir GH after OGTT, ng/mL
 Three months after NS 0.3 (0.1 − 0.8)
Fig. 1  ROC curves showing different cut-off values for random GH 
on postoperative day one (D1-rGH) for the early prediction of acro-
megaly persistence 1 year after neurosurgery. a Cut-off: 2.5 ng/mL; 
44.4% SE; 100% SP; AUC 0.783. b Cut-off: 2.1 ng/mL, 55.6% SE; 
90.9% SP; AUC 0.783. c Cut-off: 0.3 ng/mL; 100% SE; 0% SP; AUC 
0.783. SE Sensitivity, SP Specificity
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not permitted. The ROC curves displaying different cut-off 
points for D1-rGH are shown in Fig. 1.
Similarly, both the SE and SP were optimized for D2-rGH 
at a cut-off value of 0.6 ng/mL, yielding an SE of 81.8%, an 
SP of 50%, a positive LH of 1.64, a negative LH of 0.36, and 
an AUC of 0.614 ± 0.111. After maximizing the specificity 
for acromegaly persistence, a cut-off point of 2.9 ng/mL was 
identified (100% SP; 18.2% SE), but a D2-rGH > 2.9 ng/mL 
was only observed in two of 30 subjects (6.6%). A cut-off 
point of 0.1 ng/mL yielded a 100% SE and a 22.2% SP, but 
only four of 30 subjects (13.3%) had a D2-rGH of 0.1 ng/
mL, and none had a D2-rGH < 0.1 ng/mL. The ROC curves 
displaying different cut-off points for D2-rGH are shown 
in Fig. 2.
Discussion
This observational study on 41 acromegalic patients sug-
gests that serum random GH on a postoperative day one 
could be a valid and affordable test for the early prediction of 
long-term acromegaly persistence. In particular, postopera-
tive day one random GH values > 2.5 ng/mL show a posi-
tive predictive value of 100% for disease persistence. On the 
contrary, serum random GH on postoperative day two does 
not appear to be a useful predictive factor for either remis-
sion or persistence of disease, at least in the present study.
Our population shares the same characteristics as those 
described in the literature: acromegaly diagnosis in the 5th 
decade of life, a similar incidence rate between men and 
women, and macroadenomas in more than 2/3 of cases [12]. 
Moreover, the remission rate one year after surgery was 55% 
in our sample, which is similar to that reported in previ-
ous studies [12]. However, we did not find a difference in 
remission rate between micro- and macroadenomas, likely 
due to the relatively small cohort of patients, as well as the 
adenoma localization, which has not been considered.
The AACE acromegaly guidelines have suggested the 
early prediction of disease activity, recommending the use 
of postoperative fasting GH [6]; however, the recommenda-
tion n. 47 of the guidelines only has “best evidence” level 2 
(evidence obtained from limited outcome data) and Grade 
C (action based on weak evidence). Based on a single study 
[7], the AACE guidelines identified a postoperative day one 
GH cut-off point of 2 ng/mL for remission; 99% of patients 
with a postoperative GH < 2 ng/mL had clinical evidence of 
disease remission five years after NS. On the contrary, early 
prediction of disease activity and early postoperative GH 
assessment are not even mentioned in the clinical practice 
guideline of the Endocrine Society [2].
Different studies have attempted to identify early predic-
tors of disease activity, focusing on long-term remission. 
Intraoperative GH determination was initially proposed, 
indicating that a reduction in GH levels during the surgical 
procedure may improve surgical outcomes [13]; however, 
intraoperative testing is an elaborate and expensive proce-
dure and therefore is not routinely performed [13–15].
The mean of multiple GH measurements between 1 and 
3 weeks after NS appeared to be a promising high-sensitivity 
test for the prediction of a successful long-term surgical out-
come; in fact, a mean GH value < 3 ng/mL predicted disease 
remission in 100% of cases [16]. These interesting results, 
however, required multiple clinic admissions, whereas a sin-
gle early GH evaluation can be easily performed during the 
patient’s hospitalization.
Some studies have attempted to analyze the use of an 
early nadir GH after an OGTT. Although OGTT results 
become more accurate three months after NS [17], many 
authors have concluded that an early OGTT has a good posi-
tive predictive value for acromegaly remission [18, 19]. For 
example, an OGTT in the first week after NS yielded an 
81.7% SE and a 95.1% SP in diagnosing long-term remission 
[7]. Sarkar et al. evaluated both random GH on postopera-
tive day one and nadir GH after an OGTT on day seven; the 
optimal cut-off for random GH was 3.66 ng/mL (93.1% SE; 
79.2% SP) and for nadir GH was 2.55 ng/mL (93.1% SE; 
77.4% SP) [20]. Similar to the mean of multiple measure-
ments, an OGTT on day seven could also lead to time- and 
cost-consuming hospital readmission. Moreover, OGTT can-
not be performed in subjects with diabetes.
Fig. 2  ROC curves showing different cut-off values for random GH 
on postoperative day two (D2-rGH) for the early prediction of acro-
megaly persistence 1 year after neurosurgery. a Cut-off: 2.9 ng/mL; 
SE 18.2%; SP 100%; AUC 0.614. b Cut-off: 0.6 ng/mL; SE 81.8%; 
SP 50%; AUC 0.614. c Cut-off: 0.1  ng/mL; SE 100%; SP 22.2%; 
AUC 0.614. SE Sensitivity, SP Specificity
Journal of Endocrinological Investigation 
1 3
Postoperative day one random GH values < 2 ng/ml were 
highly predictive of long-term remission of acromegaly in 
a large retrospective study [21]. Other studies have ana-
lyzed the diagnostic performance of early random GH with 
different cut-off points and days of collection. Kim et al. 
measured random GH on the first three postoperative days 
after NS and found that day one was the best predictor of 
acromegaly remission [7]. Dutta et al. assessed random GH 
six hours post-NS and on days one to five after surgery; GH 
values ≤ 1.5 ng/mL at six hours showed the highest specific-
ity (83.3%) and ≤ 1.03 ng/mL on day one showed the best 
sensitivity (90.5%) [22]. The authors also found that the 
diagnostic performance of other time points was lower, with 
day four being the worst. Similarly, in our study, random GH 
on day one appeared to be a better predictor of disease status 
than that on day two.
Contrarily, Antunes et  al. found that GH lev-
els < 1.57 mcg/L on day two yielded a 93% SE and an 86% 
SP in diagnosing short-term IGF1 normalization. However, 
this study including 69 patients do not provide data on long-
term remission [23].
We note that many diagnostic tests described in the litera-
ture are not highly specific for acromegaly remission, since 
normal post-surgery GH levels could also be due to low dis-
ease activity. Therefore, switching our perspective, we used 
the ROC curves to detect patients with a higher probability 
of acromegaly persistence.
The optimal sensitivity/specificity cut-off value for the 
day one random GH yielded a low sensitivity and a high 
specificity for disease persistence. After maximizing speci-
ficity, we identified a cut-off point with a positive predictive 
value of 100% but with the limitation of a small sample 
above the cut-off.
The clinical implications of these results are relevant 
since we were able to identify patients with a very high risk 
of disease persistence, who most likely would not benefit 
from intermediate hormonal assessments, i.e., 3 months after 
pituitary surgery. Based on the limited results of our study, 
we cannot recommend any disease management alternative 
to the international guidelines, but we hypothesize that in the 
future, an early confirmation of disease activity may guide 
endocrinologists through clinical algorithms including early 
reintervention or medical therapy without delay.
The main limitation of our study is the relatively small 
sample size. However, larger studies had a retrospective 
approach; moreover, when compared with prospective 
studies, we consecutively recruited in a shorter time and 
in a single-center, focusing on long-term outcomes too. 
So, our results need to be confirmed in a larger cohort of 
patients; in particular, their reproducibility should be eval-
uated in other neurosurgical centers similar to ours, where 
a neurosurgeon with expertise in the surgical management 
of pituitary adenomas is available, as seen in the Italian 
survey on pituitary surgery [24]. It should be noted that the 
lack of uniformity of GH and IGF1 assays across different 
centers could lead to heterogeneous and non-reproducible 
data. As soon as a large sample size will be prospectively 
achieved, it would be interesting to employ a machine 
learning (ML) algorithm to early predict disease persis-
tence, based not only on D1-rGH but also on several vari-
ables. To date, few ML-based models have been proposed 
for predicting off-medication remission with high perfor-
mance. AUC of the best full model was 0.888 in a training, 
retrospective cohort of 833 patients (0.871 in the external 
cohort) [25]; similarly, AUC of the best full model was 
0.855 in a training, retrospective cohort of 534 patients 
(0.817 in the validation cohort) [26].
Interestingly, in comparison with day one, day two 
random GH had lower diagnostic performance, similar to 
observations of previous studies. In our case, the main 
reason was the limited statistical power; however, certain 
unknown biological mechanisms may be involved, since 
a time-dependent decrease in diagnostic performance has 
been observed. A lack of tumor-induced suppression of 
normal GH secretion and the effects of local factors such 
as ischemia, fibrosis, cytokines, and inflammation could 
all play a role in this interesting phenomenon and jus-
tify a “sooner the better” approach to postoperative GH 
scheduling.
In conclusion, we show that random GH on a postopera-
tive day one is a highly specific test for the early prediction 
of acromegaly persistence one year after pituitary surgery. 
After maximizing specificity, our test yields a positive pre-
dictive value of 100%, and thus predicts long-term dis-
ease persistence with a great degree of certainty. On the 
contrary, the diagnostic performance of random GH on 
postoperative day two does not demonstrate clinical utility.
We suggest an evaluation of these preliminary data in a 
broader validation sample, extending the protocol to other 
pituitary units. It is unclear whether patients with a post-
operative day one random GH > 2.5 ng/mL may benefit 
from an intermediate reassessment of disease status; how-
ever, the cut-off value must be validated prior to modifying 
the postoperative management of acromegaly. Until then, 
clinicians should follow the recommendations and timings 
suggested by the international guidelines.
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